Saikosaponin A inhibits IL-1β-induced inflammatory mediators in human osteoarthritis chondrocytes by activating LXRα

• Published in: Oncotarget Vol. 8; no. 51; pp. 88941 - 88950
• Main Authors: Gao, Hang, Song, Yanyan, Li, Dongsong, Feng, Wei, Liu, Jianguo
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 24.10.2017
• Subjects: Research Paper; LXRα; NF-κB; IL-1β; osteoarthritis chondrocyte
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.21495

Saikosaponin a (SSa), one of the main active components of , has been reported to have anti-inflammatory effect. In the present study, we investigated the anti-inflammatory effect of SSa on IL-1β-stimulated human osteoarthritis chondrocytes. The cells were pretreated with SSa 12 h before IL-1β treatment. The production of PGE2 and NO were detected by ELISA and Griess method. The levels of MMP1, MMP3, and MMP13 were measured by ELISA and qRT-PCR. The expression of NF-κB and LXRα were tested by western blot analysis. The results showed that SSa inhibited IL-1β-induced PGE2 and NO production in a concentration-dependent manner. SSa also suppressed IL-1β-induced MMP1, MMP3, and MMP13 production. Furthermore, SSa significantly attenuated IL-1β-induced phosphorylation levels of NF-κB p65 and IκBα. SSa also up-regulated the expression of LXRα. The inhibition of SSa on PGE2, NO, MMP1, MMP3, and MMP13 production were reversed by LXRα siRNA or GGPP, the inhibitor of LXRα. In conclusion, our results demonstrated that SSa inhibited inflammatory responses in human chondrocytes . SSa might be a potential therapeutic drug for osteoarthritis.